Christer Nordstedt

Christer Nordstedt is currently a Member of the Board of Directors at IRLAB Therapeutics AB and serves as the Chief Executive Officer of Oblique Therapeutics AB since November 2022. Additionally, Christer Nordstedt acts as the Chairperson of the Board of Directors at WntResearch AB. Previously, Christer served as the Interim Chief Executive Officer at Vivesto and worked as an Independent Consultant for Snevringe AB. Significant experience includes holding the position of Global Head of Specialty Research and Clinical Development at Teva Pharmaceuticals and serving as Head of R&D at Orion Corporation. Christer Nordstedt has held various board member roles in Fermion Oy and Orion Diagnostica Oy. Prior to these roles, Christer was the Vice President of CNS Research and Clinical Investigation at Eli Lilly and Company. Academic credentials include an MD and PhD in Pharmacology and Biochemistry from Karolinska Institutet and a postdoctoral fellowship in Neuroscience from The Rockefeller University.